Cargando…

Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1

BACKGROUND: Poly (ADP-ribose) polymerase inhibitors (PARPi) have become the first targeted therapies available in the treatment of patients with high-grade serous ovarian cancer (HGSOC). We recently described a significant reduction in PARP1 protein levels in vitro and in vivo in patients treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baloch, Tahira, López-Ozuna, Vanessa M., Wang, Qiong, Matanis, Emad, Kessous, Roy, Kogan, Liron, Yasmeen, Amber, Gotlieb, Walter H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327434/ https://www.ncbi.nlm.nih.gov/pubmed/30630446 http://dx.doi.org/10.1186/s12885-018-5250-4

Ejemplares similares

Biguanides in combination with olaparib limits tumorigenesis of drug‐resistant ovarian cancer cells through inhibition of Snail
por: Wang, Qiong, et al.
Publicado: (2019)

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
por: Matanes, Emad, et al.
Publicado: (2021)

Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
por: Philip, Charles-André, et al.
Publicado: (2017)

Targeted sequencing of histologically defined serous endometrial cancer reflects prognosis and correlates with preoperative biopsy
por: Octeau, David, et al.
Publicado: (2019)

Identification of Predictive Biomarkers for Lymph Node Involvement in Obese Women With Endometrial Cancer
por: López-Ozuna, Vanessa M., et al.
Publicado: (2021)

Impact of lower uterine segment involvement in type II endometrial cancer and the unique mutational profile of serous tumors
por: Kogan, Liron, et al.
Publicado: (2018)

Targeting Insulin and Insulin-Like Growth Factor Pathways in Epithelial Ovarian Cancer
por: Beauchamp, Marie-Claude, et al.
Publicado: (2010)

Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient
por: Zhang, Jian, et al.
Publicado: (2013)

Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
por: Kalachand, Roshni D., et al.
Publicado: (2020)

Occurrence of extended- spectrum β-lactamase harboring K. pneumoniae in various sources: a one health perspective
por: Yasmeen, Nafeesa, et al.
Publicado: (2023)

Role of BRCA gene dysfunction in breast and ovarian cancer predisposition
por: Scully, Ralph
Publicado: (2000)

Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study
por: Azribi, Fathi, et al.
Publicado: (2021)

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
por: Abida, Wassim, et al.
Publicado: (2020)

Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations
por: Kim, Kyung Hwan, et al.
Publicado: (2022)

Increased Risk of Hereditary Prostate Cancer in Italian Families with Hereditary Breast and Ovarian Cancer Syndrome Harboring Mutations in BRCA and in Other Susceptibility Genes
por: D’Elia, Giovanna, et al.
Publicado: (2022)

Water-Pipe Smoking Exposure Deregulates a Set of Genes Associated with Human Head and Neck Cancer Development and Prognosis
por: López-Ozuna, Vanessa M., et al.
Publicado: (2020)

Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
por: Li, Xiaofen, et al.
Publicado: (2021)

GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer
por: Galan, Alba, et al.
Publicado: (2023)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
por: Manchana, Tarinee, et al.
Publicado: (2020)

The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status
por: C.E, Drechsel Katja, et al.
Publicado: (2022)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

Emergence of bla(NDM-1) Harboring Klebsiella pneumoniae ST29 and ST11 in Veterinary Settings and Waste of Pakistan
por: Chaudhry, Tamoor Hamid, et al.
Publicado: (2020)

The BRCA Gene in Epithelial Ovarian Cancer
por: Sánchez-Lorenzo, Luisa, et al.
Publicado: (2022)

Characterization of BRCA Deficiency in Ovarian Cancer
por: Barbero, Giovanna, et al.
Publicado: (2023)

Water-pipe smoking promotes epithelial–mesenchymal transition and invasion of human breast cancer cells via ERK1/ERK2 pathways
por: Sadek, Khaled W., et al.
Publicado: (2018)

Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision
por: Lewis, Kelsey E., et al.
Publicado: (2018)

Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
por: Arakelyan, Arsen, et al.
Publicado: (2021)

Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations
por: Hsu, Ping-Chih, et al.
Publicado: (2022)

New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study
por: Plaskocinska, Inga, et al.
Publicado: (2016)

Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan
por: Hamdani, Syed Abdul Mannan, et al.
Publicado: (2022)

Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation
por: Guyonnet, Emma, et al.
Publicado: (2023)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2
por: Samuel, David, et al.
Publicado: (2022)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
por: O’Mahony, Denise G., et al.
Publicado: (2023)

Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors
por: Amin, Oreekha, et al.
Publicado: (2015)

Ductal Carcinoma In Situ (DCIS) Diagnosed by MRI-Guided Biopsy among BRCA1/BRCA2 Mutation Carriers
por: Faermann, Renata, et al.
Publicado: (2022)

BRCA mutations in the manifestation and treatment of ovarian cancer
por: Pan, Zimin, et al.
Publicado: (2017)

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
por: Ligtenberg, M J L, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_bkc3hseu7m88fihk84jm1h6tst